CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Duobrii®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04720105
NCT04720105Phase 4Completed
CompareCT.gov

Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet

Icahn School of Medicine at Mount Sinai·interventional·Posted Jan 22, 2021·Updated Oct 27, 2023

In Brief

A Phase 4 clinical trial evaluating Duobrii® for Palmoplantar Psoriasis and Plaque Psoriasis. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPalmoplantar Psoriasis, Plaque Psoriasis
CountriesUnited States
CollaboratorsBausch Health Americas, Inc.

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJan 22, 2021
Enrollment StartNov 19, 2020
Primary CompletionMar 29, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago

Interventions

Duobrii®drug

Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.